Please login to the form below

Not currently logged in
Email:
Password:

Cipla invests £100m in UK

Indian pharma company to fund both commercial and R&D activities
UK flag

India-based pharma company Cipla has made inroads into the UK with a £100m investment in both research and commercial areas.

Cipla, which is best known for its pioneering role in providing HIV treatment to developing nations, intends to launch a range of drugs in respiratory, oncology and antiretroviral indications.

The company will also put money towards R&D, clinical trials and further expansion in the UK in what is a sign of confidence in the country's ability to attract pharma investment following downsizing by the likes of Pfizer and Novartis.

UK Chancellor of the Exchequer George Osborne said: “Cipla is one of India's leading pharmaceutical firms and this decision shows the UK's international strength and attractiveness in this sector as well as its growing importance in Cipla's long term strategy.”

Cipla's chief financial officer Rajesh Garg explained that the company was attracted by the strength of the UK's NHS and by recent government efforts to improve the research environment, including the Life Sciences Strategy.

“We are very pleased to be making this investment in the UK,” said Garg. “We were impressed with the pro-active support and engagement that the UK Government and its various ministries showed in attracting Cipla to choose the UK as a key hub in our global footprint.”

11th July 2014

From: Research, Sales, Healthcare

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

5 ways we’re enhancing our services to support our clients in 2023
Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023....
ASH 2022: bad blood but big advances
Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...
Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....